幹細胞製造の世界市場-2025～2032年

幹細胞製造の世界市場は、2024年に162億3,000万米ドルに達し、2032年には404億米ドルに達すると予測され、予測期間2025年のCAGRは11.5%で成長すると予測されています。

世界の幹細胞製造市場は、研究や治療用途を含む様々な用途のために、管理された条件下で幹細胞の組織的生産に関与する部門を指します。この市場には、胚性幹細胞、成体幹細胞、人工多能性幹細胞（iPSC）など、さまざまな種類の幹細胞を分離、拡大、保存するプロセス全体が含まれます。

この市場には、高度なバイオプロセス技術を利用した、様々な供給源からの幹細胞の製造に関する活動が含まれます。これらのプロセスには、幹細胞が研究や臨床応用のための厳格な品質・安全基準を満たしていることを確認するための培養、精製、検査が含まれます。これらの要因が、世界の幹細胞製造市場拡大の原動力となっています。

市場力学：

促進要因と抑制要因

幹細胞製造におけるイノベーション

幹細胞製造の技術革新は、世界の幹細胞製造市場の成長を促進する上で重要な役割を果たしており、予測期間を通じてこの成長を促進し続けると予測されています。

細胞培養法の継続的な進歩は、幹細胞の成長と維持を強化します。3D細胞培養のような技術は、細胞の行動や機能性を改善し、より生理学的に適切な環境を作り出します。この技術革新により、幹細胞の収量が増加し、品質が向上するため、治療への応用に適しています。

高度なバイオリアクターシステムの開発により、管理された条件下での幹細胞の大量生産が容易になりました。これらのシステムは、pH、温度、酸素レベルなどの環境パラメーターの監視と調整を自動化し、最適な増殖条件を確保します。この自動化によって人為的ミスやばらつきが減り、より一貫した信頼性の高い細胞生産が可能になります。

凍結保存法の革新は、幹細胞の長期保存と生存性を向上させます。改良された凍結技術により、細胞は解凍後もその機能を維持し、将来的な利用可能性が拡大します。この能力は、高品質な幹細胞を効率的に保存・輸送する必要がある治療法の開発にとって極めて重要です。CRISPRのようなツールは、遺伝子レベルでの正確な改変を可能にし、幹細胞の治療可能性を高めます。これらの技術により、研究者はより効果的で安全な幹細胞ベースの治療法を開発することが可能となり、再生医療への応用が拡大します。

さらに、業界の主要企業は、革新的な製品の発売や地理的な拡大を行い、世界の幹細胞製造市場を牽引しています。例えば、2023年10月、Bayer's Cell Therapyはカリフォルニア州バークレーに製造施設を立ち上げました。この施設は再生医療、特に細胞療法と遺伝子療法に特化した最先端の製造施設です。この施設は、深刻な病状に対する革新的な治療法の開発と製造を支援することを目的とした総額2億5,000万米ドルのバイオテクノロジーへの重要な投資です。

また、Pluri Inc.は2024年1月、細胞治療薬製造に特化した開発製造受託機関（CDMO）サービスを提供する新部門、PluriCDMOの立ち上げを発表しました。この戦略的な動きは、市場規模が52億米ドルに達すると予測される急成長中の細胞・遺伝子治療分野でのPluriの能力を強化することを目的としています。世界の幹細胞製造市場の需要は、治療と研究の進歩におけるその重要性を強調する様々な要因によって牽引されています。

さらに、人工多能性幹細胞（iPSC）の出現による需要の高まりが、幹細胞製造の世界市場拡大に寄与しています。

高い運用コスト

幹細胞製造の世界市場における最も重要な課題の一つは、幹細胞生産に関連するコストの高さです。このようなコストは、従来の医薬品製造のコストを上回ることが多く、幹細胞製品へのアクセスや市場への浸透を制限する要因となっています。

幹細胞治療の費用は、使用される幹細胞の種類、投与量、細胞の質、治療施設の場所、幹細胞の供給源など、いくつかの要因によって大きく異なります。平均して、患者は幹細胞治療のために5,000ドルから50,000ドルを支払うと予想されます。一方、血小板を豊富に含む血漿（PRP）を利用する場合、同じ治療セッションで関節やケガの追加治療を行うのにかかる費用は、それぞれ800ドル程度です。2023年には、拡大細胞製剤を用いた幹細胞治療の最も一般的な価格帯は、15,000ドルから30,000ドルの間でした。

幹細胞製造の複雑な性質は、細胞の単離、膨張、分化、凍結保存といった複数の複雑なプロセスを含んでいます。各工程では、細部にまで細心の注意を払い、規制基準を遵守する必要があるため、人件費や材料費がかさむことになります。ある報告によると、ヒト間葉系間質細胞／幹細胞（hMSCs）の製造コストは、最適化されたプロセスを用いた場合、大規模で100万細胞あたり1～5ドルになる可能性があります。従って、上記の要因が世界の幹細胞製造市場の潜在的な成長を制限している可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 幹細胞製造におけるイノベーション
  • 抑制要因
    • 高い運用コスト
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 特許分析
• 規制分析
• SWOT分析
• アンメットニーズ

第6章 製品別

• 成体幹細胞（ASC）
  • 造血幹細胞（HSC）
  • 間葉系幹細胞（MSC）
  • 神経幹細胞
  • 上皮/皮膚幹細胞
• ヒト胚性幹細胞（HESC）
• 人工多能性幹細胞（iPSC）
• 非常に小さな胚様幹細胞
• 消耗品
  • 培養培地
  • 試薬
  • その他
• 機器
  • バイオリアクター
  • インキュベーター
  • セルソーター
  • その他

第7章 用途別

• 再生医療
• 創薬と開発
• 研究用途
• 細胞・組織バンキング

第8章 技術別

• 細胞獲得
• 細胞生産
• 凍結保存
• 拡大および分割培養

第9章 治療の種類別

• 自家療法
• 他家療法

第10章 エンドユーザー別

• 製薬・バイオテクノロジー企業
• 病院と診療所
• 幹細胞バンク
• 研究機関

第11章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州地域
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第12章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第13章 企業プロファイル

• Thermo Fisher Scientific Inc.
  • 会社概要
  • 製品ポートフォリオ
    • 製品説明
    • 製品の主要業績評価指標（KPI）
    • 過去および予測の製品販売
    • 製品販売量
  • 財務概要
    • 会社の収益
    • 地域別収益分配
    • 収益予測
  • 主な発展
    • 合併と買収
    • 主な製品開発活動
    • 規制当局の承認等
  • SWOT分析
• Merck KGaA
• Lonza Group Ltd.
• DH Life Sciences, LLC.
• Sartorius AG
• Becton, Dickinson and Company（BD）
• Eppendorf SE
• Corning Incorporated
• Bio-Rad Laboratories, Inc.
• Fujifilm Holdings Corporation（Cellular Dynamics）

第14章 付録

The global stem cell manufacturing market reached US$ 16.23 billion in 2024 and is expected to reach US$ 40.40 billion by 2032, growing at a CAGR of 11.5% during the forecast period 2025-2032.

The global stem cell manufacturing market refers to the sector involved in the systematic production of stem cells under controlled conditions for various applications, including research and therapeutic uses. This market encompasses the entire process of isolating, expanding, and preserving different types of stem cells, such as embryonic stem cells, adult stem cells, and induced pluripotent stem cells (iPSCs).

The market includes activities related to the manufacturing of stem cells from various sources, utilizing advanced bioprocessing techniques. These processes involve culturing, purifying, and testing stem cells to ensure they meet stringent quality and safety standards for research and clinical applications. These factors have driven the global stem cell manufacturing market expansion.

Market Dynamics: Drivers & Restraints

Innovations in Stem Cell Manufacturing

Innovations in stem cell manufacturing are playing a crucial role in driving the growth of the global stem cell manufacturing market and are anticipated to continue fueling this growth throughout the forecast period.

Continuous advancements in cell culture methods enhance the growth and maintenance of stem cells. Techniques like 3D cell culture create more physiologically relevant environments that improve cell behavior and functionality. This innovation leads to higher yields and better quality stem cells, making them more suitable for therapeutic applications.

The development of sophisticated bioreactor systems facilitates large-scale production of stem cells under controlled conditions. These systems automate the monitoring and adjustment of environmental parameters such as pH, temperature, and oxygen levels, ensuring optimal growth conditions. This automation reduces human error and variability, resulting in more consistent and reliable cell production.

Innovations in cryopreservation methods enhance the long-term storage and viability of stem cells. Improved freezing techniques ensure that cells maintain their functionality after thawing, expanding their availability for future use. This capability is crucial for developing therapies that require high-quality stem cells to be stored and transported efficiently. Tools such as CRISPR allow for precise modifications at the genetic level, enhancing the therapeutic potential of stem cells. These technologies enable researchers to create more effective and safer stem cell-based treatments, thus expanding their application in regenerative medicine.

Furthermore, key players in the industry have innovative product launches and geographical expansion that would drive the global stem cell manufacturing market. For instance, in October 2023, Bayer's Cell Therapy launched a manufacturing facility in Berkeley, California, which is a state-of-the-art facility dedicated to the production of regenerative medicines, particularly focusing on cell and gene therapies. This facility represents a significant investment in biotechnology, with a total expenditure of $250 million aimed at supporting the development and manufacturing of innovative treatments for serious medical conditions.

Also, in January 2024, Pluri Inc., announced the launch of PluriCDMO, a new division focused on providing Contract Development and Manufacturing Organization (CDMO) services specifically for cell therapy manufacturing. This strategic move aims to enhance Pluri's capabilities in the rapidly growing field of cell and gene therapies, which is projected to reach a market value of $5.2 billion. The demand for the global stem cell manufacturing market is driven by a combination of factors that highlight its significance in advancing medical treatments and research.

Moreover, the rising demand for the emergence of induced pluripotent stem cells (iPSCs) contributes to the global stem cell manufacturing market expansion.

High Operational Costs

One of the most significant challenges in the global stem cell manufacturing market is the high costs associated with stem cell production. These expenses often surpass those of traditional pharmaceutical manufacturing due to several contributing factors, which can limit the accessibility and market penetration of stem cell products.

The cost of stem cell therapy can vary widely based on several factors, including the type of stem cells used, the quantity administered, the quality of the cells, the location of the treatment facility, and the source of the stem cells. On average, patients can expect to pay between $5,000 and $50,000 for stem cell therapy. For specific treatments, a single stem cell injection typically costs around $4,000, while treating additional joints or injuries during the same session can cost as little as $800 each when utilizing platelet-rich plasma (PRP). In 2023, the most common price range for stem cell therapy involving expanded cell products was between $15,000 and $30,000.

The complex nature of stem cell manufacturing involves multiple intricate processes such as cell isolation, expansion, differentiation, and cryopreservation. Each step requires meticulous attention to detail and adherence to regulatory standards, which can increase labor and material costs. A report indicated that manufacturing costs for human mesenchymal stromal/stem cells (hMSCs) could range from $1 to $5 per million cells at large scales when using optimized processes; however, these costs can be significantly higher in traditional systems. Thus, the above factors could be limiting the global stem cell manufacturing market's potential growth.

Segment Analysis

The global stem cell manufacturing market is segmented based on product, application, technology, therapy type, end-user, and region.

Product:

The adult stem cells (ASCs) segment is expected to dominate the global stem cell manufacturing market share

The adult stem cells (ASCs) segment holds a major portion of the global stem cell manufacturing market share and is expected to continue to hold a significant portion of the global stem cell manufacturing market share during the forecast period.

The global stem cell manufacturing market includes various types of stem cells, with adult stem cells (ASCs) playing a crucial role in regenerative medicine. ASCs are undifferentiated cells located in various tissues that can differentiate into specialized cell types, offering significant therapeutic potential. This segment encompasses several specific types of adult stem cells, each with unique characteristics and applications.

Types of adult stem cells include hematopoietic stem cells (HSCs), mesenchymal stem cells (MSCs), neural stem cells, and epithelial/skin stem cells. The increasing prevalence of chronic diseases and the rising demand for regenerative therapies are driving growth within the ASC segment of the stem cell manufacturing market. Advancements in technology related to cell culture techniques and bioreactor systems enhance the scalability and efficiency of producing these stem cells.

The segment of adult stem cells within the global stem cell manufacturing market is vital due to its extensive applications in treating a variety of diseases and conditions. As technology continues to advance and regulatory frameworks evolve, the potential for ASCs to contribute significantly to regenerative medicine will likely expand. However, addressing challenges such as high production costs and regulatory complexities will be essential for maximizing their therapeutic potential and ensuring broader accessibility for patients.

Furthermore, key players in the industry have innovative launches and expansion that would propel this segment's growth in the global stem cell manufacturing market. For instance, in May 2024, REPROCELL announced the launch of Master Cell Bank (MCB) manufacturing services specifically for Human Induced Pluripotent Stem Cells (hiPSCs) and Human Mesenchymal Stem Cells (hMSCs). This initiative is designed to support the growing demands of the regenerative medicine and therapeutic sectors.

Also, in July 2024, STEMCELL Technologies introduced the CellPore Transfection System, a groundbreaking technology designed to advance cell engineering research and facilitate the development of novel cell therapies aimed at curing diseases. This innovative system utilizes a method known as mechanoporation for delivering various cargo into mammalian cells. These factors have solidified the segment's position in the global stem cell manufacturing market.

Geographical Analysis

North America is expected to hold a significant position in the global stem cell manufacturing market share

North America holds a substantial position in the global stem cell manufacturing market and is expected to hold most of the market share.

The rising incidence of chronic conditions such as diabetes, cancer, and neurological disorders is a major driver for the stem cell manufacturing market. For instance, it is projected that cancer cases in North America will rise by 45% between 2020 and 2040, creating a substantial need for innovative treatments. As these diseases become more prevalent, the demand for effective regenerative therapies, including stem cell-based treatments, continues to grow.

Continuous improvements in stem cell manufacturing technologies, including advancements in cell culture techniques, bioreactor systems, and automation, have enhanced the efficiency and scalability of producing stem cells. These innovations facilitate higher yields and improved quality of stem cells, making them more suitable for therapeutic applications.

The regulatory framework in North America, particularly through initiatives like the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation, has accelerated the approval process for stem cell therapies. Between 2019 and 2023, there was a 40% increase in RMAT designations, which fosters a supportive environment for investment and innovation in stem cell research and manufacturing.

The presence of leading biotechnology companies and research institutions in North America provides a solid foundation for advancing stem cell research and manufacturing. In 2023, biotechnology companies invested over $12 billion in stem cell research, representing a 35% increase from 2020. This infrastructure supports extensive clinical trials and collaborations that drive innovation in stem cell technologies.

Furthermore, key players in the industry investments and key initiatives that would propel this global stem cell manufacturing market growth. For instance, in October 2024, OmniaBio officially opened a new commercial manufacturing facility in Hamilton, Ontario, marking a significant milestone in the Canadian biotechnology landscape. This state-of-the-art facility is now the largest of its kind in Canada, dedicated to the production of cell and gene therapies (CGT), and aims to enhance access to life-saving treatments for patients.

The facility's inaugural commercial-stage customer is MEDIPOST, a recognized leader in stem cell therapeutics. MEDIPOST plans to manufacture CARTISTEM, an allogeneic umbilical cord blood-derived mesenchymal stem cell product, at OmniaBio's Hamilton site. CARTISTEM is specifically used to treat knee cartilage defects in patients suffering from osteoarthritis caused by degeneration. Thus, the above factors are consolidating the region's significant position in the global stem cell manufacturing market.

Asia Pacific is growing at the fastest pace in the global stem cell manufacturing market share

Asia Pacific holds the fastest pace in the global stem cell manufacturing market and is expected to hold most of the market share.

The increasing incidence of chronic diseases, such as cancer and cardiovascular conditions, is driving demand for advanced medical treatments, including stem cell therapies. The region's growing population and aging demographics further exacerbate this need, necessitating innovative therapeutic solutions.

Many countries in the Asia-Pacific region, particularly China, Japan, South Korea, and India, have implemented supportive government policies to promote biotechnology and stem cell research. For instance, the Chinese government has allocated approximately $18 billion to biotechnology research in its latest five-year plan, significantly boosting stem cell initiatives. These initiatives encourage investment and innovation in stem cell therapies.

The expansion and modernization of healthcare infrastructure across Asia-Pacific countries enhance the capacity for stem cell research and manufacturing. Investments in state-of-the-art facilities and technology enable better production processes and quality control, facilitating the development of effective stem cell therapies.

The development of iPSCs is revolutionizing the field by providing an alternative to embryonic stem cells, reducing ethical concerns while expanding research possibilities. iPSCs can be generated from adult cells, making them a versatile tool for regenerative medicine. Partnerships between industry players and academic institutions are fostering innovation in stem cell research. Collaborative efforts enhance knowledge sharing, accelerate clinical trials, and facilitate the transition from research to market-ready therapies.

Countries like India and Thailand are becoming popular destinations for medical tourism, particularly for patients seeking advanced treatments like stem cell therapy at competitive prices. This trend increases demand for stem cell manufacturing capabilities within these countries.

Furthermore, key players in the industry product launches and investments that would propel this global stem cell manufacturing market growth. For instance, in July 2024, Bioserve India announced the launch of advanced stem cell products from REPROCELL, aimed at enhancing scientific research, drug development, and regenerative medicine in India. This initiative marks a significant step forward in the country's biotechnology landscape, providing researchers and clinicians with access to cutting-edge tools and technologies designed to support innovative medical advancements.

Also, in August 2024, Cryoviva (Thailand) launched its "World Class" laboratory, significantly expanding its capabilities by tripling its original size. This expansion is aimed at meeting the increasing production needs for Advanced Therapy Medicinal Products (ATMP) under Good Manufacturing Practice (GMP) and Pharmaceutical Inspection Co-operation Scheme (PICS) standards. Thus, the above factors are consolidating the region's position as the fastest-growing force in the global stem cell manufacturing market.

Competitive Landscape

The major global players in the stem cell manufacturing market include Thermo Fisher Scientific Inc., Merck KGaA, Lonza Group Ltd., DH Life Sciences, LLC., Sartorius AG, Becton, Dickinson and Company (BD), Eppendorf SE, Corning Incorporated, Bio-Rad Laboratories, Inc., and Fujifilm Holdings Corporation (Cellular Dynamics) among others.

Key Developments

• In October 2024, Aspen Neuroscience, Inc. announced the expansion of its operations with a new 22,000-square-foot facility located near its headquarters in Torrey Pines, San Diego. This new facility is designed to enhance the company's capabilities in producing personalized cell therapies derived from induced pluripotent stem cells (iPSCs), specifically targeting the treatment of Parkinson's disease.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global stem cell manufacturing market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product
• 3.2. Snippet by Application
• 3.3. Snippet by Technology
• 3.4. Snippet by Therapy Type
• 3.5. Snippet by End-User
• 3.6. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Innovations in Stem Cell Manufacturing
  • 4.1.2. Restraints
    • 4.1.2.1. High Operational Costs
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Patent Analysis
• 5.5. Regulatory Analysis
• 5.6. SWOT Analysis
• 5.7. Unmet Needs

6. By Product

• 6.1. Introduction
  • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product
  • 6.1.2. Market Attractiveness Index, By Product
• 6.2. Adult Stem Cells (ASCs)*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.2.3. Hematopoietic Stem Cells (HSCs)
  • 6.2.4. Mesenchymal Stem Cells (MSCs)
  • 6.2.5. Neural Stem Cells
  • 6.2.6. Epithelial/Skin Stem Cells
• 6.3. Human Embryonic Stem Cells (HESCs)
• 6.4. Induced Pluripotent Stem Cells (iPSCs)
• 6.5. Very Small Embryonic-Like Stem Cells
• 6.6. Consumables
  • 6.6.1. Culture media
  • 6.6.2. Reagents
  • 6.6.3. Others
• 6.7. Instruments
  • 6.7.1. Bioreactors
  • 6.7.2. Incubators
  • 6.7.3. Cell Sorters
  • 6.7.4. Others

7. By Application

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 7.1.2. Market Attractiveness Index, By Application
• 7.2. Regenerative Medicine*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Drug Discovery and Development
• 7.4. Research Applications
• 7.5. Cell and Tissue Banking

8. By Technology

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 8.1.2. Market Attractiveness Index, By Technology
• 8.2. Cell Acquisition*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Cell Production
• 8.4. Cryopreservation
• 8.5. Expansion and Sub-Culture

9. By Therapy Type

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
  • 9.1.2. Market Attractiveness Index, By Therapy Type
• 9.2. Autologous Therapy*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Allogenic Therapy

10. By End-User

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.1.2. Market Attractiveness Index, By End-User
• 10.2. Pharmaceutical and Biotechnology Companies*
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Hospitals and Clinics
• 10.4. Stem Cell Banks
• 10.5. Research Institutions

11. By Region

• 11.1. Introduction
  • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 11.1.2. Market Attractiveness Index, By Region
• 11.2. North America
  • 11.2.1. Introduction
  • 11.2.2. Key Region-Specific Dynamics
  • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
  • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.2.8.1. U.S.
    • 11.2.8.2. Canada
    • 11.2.8.3. Mexico
• 11.3. Europe
  • 11.3.1. Introduction
  • 11.3.2. Key Region-Specific Dynamics
  • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
  • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.3.8.1. Germany
    • 11.3.8.2. U.K.
    • 11.3.8.3. France
    • 11.3.8.4. Spain
    • 11.3.8.5. Italy
    • 11.3.8.6. Rest of Europe
• 11.4. South America
  • 11.4.1. Introduction
  • 11.4.2. Key Region-Specific Dynamics
  • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
  • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.4.8.1. Brazil
    • 11.4.8.2. Argentina
    • 11.4.8.3. Rest of South America
• 11.5. Asia-Pacific
  • 11.5.1. Introduction
  • 11.5.2. Key Region-Specific Dynamics
  • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
  • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.5.8.1. China
    • 11.5.8.2. India
    • 11.5.8.3. Japan
    • 11.5.8.4. South Korea
    • 11.5.8.5. Rest of Asia-Pacific
• 11.6. Middle East and Africa
  • 11.6.1. Introduction
  • 11.6.2. Key Region-Specific Dynamics
  • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
  • 11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. Competitive Landscape

• 12.1. Competitive Scenario
• 12.2. Market Positioning/Share Analysis
• 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

• 13.1. Thermo Fisher Scientific Inc.*
  • 13.1.1. Company Overview
  • 13.1.2. Product Portfolio
    • 13.1.2.1. Product Description
    • 13.1.2.2. Product Key Performance Indicators (KPIs)
    • 13.1.2.3. Historic and Forecasted Product Sales
    • 13.1.2.4. Product Sales Volume
  • 13.1.3. Financial Overview
    • 13.1.3.1. Company Revenue's
    • 13.1.3.2. Geographical Revenue Shares
    • 13.1.3.3. Revenue Forecasts
  • 13.1.4. Key Developments
    • 13.1.4.1. Mergers & Acquisitions
    • 13.1.4.2. Key Product Development Activities
    • 13.1.4.3. Regulatory Approvals etc.
  • 13.1.5. SWOT Analysis
• 13.2. Merck KGaA
• 13.3. Lonza Group Ltd.
• 13.4. DH Life Sciences, LLC.
• 13.5. Sartorius AG
• 13.6. Becton, Dickinson and Company (BD)
• 13.7. Eppendorf SE
• 13.8. Corning Incorporated
• 13.9. Bio-Rad Laboratories, Inc.
• 13.10. Fujifilm Holdings Corporation (Cellular Dynamics)

LIST NOT EXHAUSTIVE

14. Appendix

• 14.1. About Us and Services
• 14.2. Contact Us